In this regard, the co-inhibition of FAK and BRD4 may lead to impaired activation of dynamics of T regulatory cell populations and IL8-linked NF-KB network in NSCLC adenocarcinomas, including those with KRAS mutations (Sunaga et al., 2012; Adeegbe et al., 2017). Here, KRAS is linked to non-small cell lung carcinoma.